Wolfram E Samlowski (Wolfram Samlowski)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 15

Top Topics

Irritable Bowel Syndrome

Clostridium Difficile

Prognostic Factors

Top Venues

Current oncology (Toronto, Ont.)

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Clarice Ho, Wolfram E Samlowski
Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. Current oncology (Toronto, Ont.) 31 (6) (2024)
Clarice Ho, Wolfram E Samlowski
Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. Current oncology (Toronto, Ont.) 31 (6) (2024)
Clarice Ho, Wolfram E Samlowski
Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. Current oncology (Toronto, Ont.) 31 (6) (2024)
Wolfram E Samlowski
The Effect of Non-Overlapping Somatic Mutations in BRAF , NRAS , NF1 , or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma. Cancers 16 (3) (2024)
Wolfram E Samlowski
The Effect of Non-Overlapping Somatic Mutations in BRAF , NRAS , NF1 , or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma. Cancers 16 (3) (2024)
Alyssa Panning, Wolfram E Samlowski, Gabriel Allred
Lack of Influence of Non-Overlapping Mutations in BRAF , NRAS , or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma. Cancers 15 (13) (2023)
Kaviyon Sadrolashrafi, Wolfram E Samlowski
Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. The oncologist (2023)
Raquel Wescott, Wolfram E Samlowski
Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series. Current oncology (Toronto, Ont.) 30 (10) (2023)
Sandip Pravin Patel, Megan K D Othus, Young Kwang Chae, Michael J Dennis, Sarah Gordon, David G Mutch, Wolfram E Samlowski, William R Robinson, Elad Sharon, Christopher Ryan, Gabby Lopez, Melissa Plets, Charles David Blanke, Razelle Kurzrock
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Leanne Perez, Wolfram E Samlowski, Ruby Lopez-Flores
Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data. Biomedicines 10 (5) (2022)
Wolfram E Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Emilie Scherrer, Mizuho Fukunaga-Kalabis, Clemens Krepler, Ruixuan Jiang
Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics. Future oncology (London, England) (2022)
Wolfram E Samlowski, Nicholas J Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S Weber
Real-World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer medicine (2022)
Wolfram E Samlowski, Camille Adajar
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC cancer 21 (1) (2021)
Joshua P Weissman, Wolfram E Samlowski, Raul Meoz
Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series. The oncologist 26 (12) (2021)
Wolfram E Samlowski, James Moon, Merle Witter, Michael B Atkins, John M Kirkwood, Megan Othus, Antoni Ribas, Vernon K Sondak, Lawrence E Flaherty
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer medicine 6 (11) (2017)